Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$17,500.00

Development of a CRISPR-Cas9 strategy to investigate the role of p53 mutations in regulating expression of estrogen receptor alpha in breast cancer cells

EF 2017-18

Résumé
Background: Estrogen receptor alpha (ERa) is expressed heterogeneously in breast tumors, but the mechanisms controlling its expression are still poorly understood. Transcription factor p53 is a known regulator of ERa expression that is frequently mutated in breast cancer (BC). It is unclear however whether mutations in p53 are sufficient to abrogate ER expression.Rationale and objective: The CRISPR-Cas9 technology enables introduction of mutations via targeted homologous recombination. We will use this technology to introduce point mutations of p53 in the ER+ MCF7 breast cancer cell line and test the impact of these mutations on ERa expression.Experimental approach:- p53 point mutations will be selected based on preferential occurrence in ER- vs ER+ tumors and location close to a PAM site needed for Cas9 endonuclease activity. Single stranded donor oligonucleotide templates carrying these mutations will be designed.- Guide RNAs and homologous recombination templates will be transfected in MCF7 cells that express Cas9 in an inducible manner.- Clones will be isolated from transfected cells by limiting dilution, amplified and characterized for the presence of the desired mutation in at least one allele of TP53.- ERa expression will be assessed at the RNA and protein levels.Expected impact and future studies: This study should indicate whether specific mutations in p53 are sufficient to convert an ER+ to an ER- subtype, or indicate a need for additional events.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
386660
Name
Canapi Leanna T
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Development of a CRISPR-Cas9 strategy to investigate the role of p53 mutations in regulating expression of estrogen receptor alpha in breast cancer cells
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Crispr-Cas9; Estrogen Receptor Alpha; Molecular Screening; P53
Abstract
Background: Estrogen receptor alpha (ERa) is expressed heterogeneously in breast tumors, but the mechanisms controlling its expression are still poorly understood. Transcription factor p53 is a known regulator of ERa expression that is frequently mutated in breast cancer (BC). It is unclear however whether mutations in p53 are sufficient to abrogate ER expression.Rationale and objective: The CRISPR-Cas9 technology enables introduction of mutations via targeted homologous recombination. We will use this technology to introduce point mutations of p53 in the ER+ MCF7 breast cancer cell line and test the impact of these mutations on ERa expression.Experimental approach:- p53 point mutations will be selected based on preferential occurrence in ER- vs ER+ tumors and location close to a PAM site needed for Cas9 endonuclease activity. Single stranded donor oligonucleotide templates carrying these mutations will be designed.- Guide RNAs and homologous recombination templates will be transfected in MCF7 cells that express Cas9 in an inducible manner.- Clones will be isolated from transfected cells by limiting dilution, amplified and characterized for the presence of the desired mutation in at least one allele of TP53.- ERa expression will be assessed at the RNA and protein levels.Expected impact and future studies: This study should indicate whether specific mutations in p53 are sufficient to convert an ER+ to an ER- subtype, or indicate a need for additional events.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Canapi, Leanna T
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~